[Featured Stock] PharmGen Science Hits Upper Limit... MOU with US Company for COVID-19 Vaccine Development

[Asia Economy Reporter Park Soyeon] PharmGen Science is hitting the upper price limit.

As of 2:39 PM on the 23rd, PharmGen Science is trading at 13,650 KRW, up 3,150 KRW (30%) from the previous trading day on the KOSPI market.

PharmGen Science announced on the same day that on the 21st (local time in the US), it attended the "Korea-US Global Vaccine Partnership" hosted by the government in New York, USA, and signed an MOU for "joint development and commercialization of a COVID-19 vaccine" with its US-based subsidiary Access Bio and US venture IVY Pharma.

PharmGen Science was established in 1966 and listed in 1990. Headquartered in Hwaseong, Gyeonggi Province, it is engaged in pharmaceutical manufacturing and wholesale and retail distribution. Its main products include Bardipin, Telodipin, Livatin, Kvastin, Arsidin-F, Esomax, and Neizatin.

PharmGen Science has a market capitalization of 200.8 billion KRW and ranks 632nd on the KOSPI.